Sonomind raises €3 million to advance its innovative ultrasound-based neuromodulation device aimed at treating medication-resistant depression, opening new therapeutic possibilities in psychiatry.
Target Information
Sonomind is a pioneering medical technology company established in 2024, focused on developing a unique non-invasive brain stimulation device utilizing ultrasound. The company recently raised €3 million, including €2 million in equity funding during a seed round led by Critical Path Ventures. Additionally, it received €1 million in non-dilutive funding from the French government as part of the France 2030 initiative aimed at nurturing deep tech innovations.
The funds obtained will further the development of Sonomind's personalized low-intensity ultrasound therapy platform. In the coming months, the company plans to initiate clinical trials to test its technology in treating medication-resistant depression.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
The mental health market is a significant public health issue, with the World Health Organization reporting that depression affects approximately 330 million individuals globally, making it one of the leading causes of disability. In F
Similar Deals
Kurma Partners, WE Life Sciences, Bpifrance, Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est, Sambrinvest → Elkedonia
2025
GO Capital and Critical Path Ventures → Alkion BioInnovations
2025
Kurma Partners, WE Life Sciences, French Tech Seed fund → Elkedonia
2025
Critical Path Ventures
invested in
Sonomind
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $3M
Equity Value: $2M